DocDollars

Veloxis Pharmaceuticals, Inc.

NC · United States · Reporting entity ID 100000151661

Total reported 2019–2025
$10.6M
#473 of 2,960 reporting companies — 0% of all reported industry payments
$2.41M in general payments across 7,675 records, plus $8.20M in research funding across 281 records.

How it breaks down

General payments $2,409,476
Research funding $8,199,623

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Veloxis Pharmaceuticals, Inc. reported $10.6M to US doctors and teaching hospitals from 2019 to 2025, ranking #473 of 2,960 reporting companies. 77% of that was research funding and 23% general payments such as consulting, speaking, food and travel. 7,675 general payment records and 281 research records were filed.

Common questions about Veloxis Pharmaceuticals, Inc.

How much has Veloxis Pharmaceuticals, Inc. paid US doctors?

Veloxis Pharmaceuticals, Inc. reported $10,609,099 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $2,409,476 in general payments, $8,199,623 in research funding.

How does Veloxis Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #473 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Veloxis Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.